Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma.

ABSTRACT:

Background

Glioma O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status informs clinical decision making. Worldwide different methods and cutoff levels are used, which can lead to discordant methylation results.

Methods

We conducted an international survey to clarify which methods are regularly used and why. We also explored opinions regarding international consensus on methods and cutoff.

Results

The survey had 152 respondents from 25 countries. MGMT methylation status is determined for all glioblastomas in 37% of laboratories. The most common methods are methylation-specific polymerase chain reaction (msPCR) (37%) and pyrosequencing (34%). A method is selected for simplicity (56%), cost-effectiveness (50%), and reproducibility of re

SUBMITTER: Malmstrom A 

PROVIDER: S-EPMC6993038 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature